Pitavastatin Combined with Ezetimibe Treatment was an Effective Approach to Non-IRA Lesion of ST-segment Elevation Myocardial Infarction Patients with Primary Percutaneous Coronary Intervention
| Autor: | Guang Ping Li, Li Cheng Lei, Jian Jun Peng, Li Hui Ren, Bo Zhao, Hui Ming Ye, Zuo Yan Wang, Sheng Zhao |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
medicine.medical_specialty Statin Critical Care medicine.drug_class medicine.medical_treatment Pharmaceutical Science Revascularization Percutaneous Coronary Intervention Ezetimibe Risk Factors Internal medicine medicine ST segment Humans cardiovascular diseases Myocardial infarction Stroke Aged business.industry Anticholesteremic Agents Percutaneous coronary intervention Middle Aged medicine.disease Combined Modality Therapy Lipoproteins LDL surgical procedures operative Cholesterol Treatment Outcome Conventional PCI Cardiology Quinolines ST Elevation Myocardial Infarction Female Hydroxymethylglutaryl-CoA Reductase Inhibitors business Biotechnology medicine.drug Follow-Up Studies |
| Zdroj: | Current pharmaceutical biotechnology. 22(4) |
| ISSN: | 1873-4316 |
| Popis: | Objective: ST-Segment Elevation Myocardial Infarction (STEMI) patients with the multivessel disease have distinctive plaque characteristics in non-IRA lesions. Intensive statin therapy was a potential approach to treat STEMI patients with the non-IRA disease. However, there is still poor evidence about the therapeutic effect. In this study, we have evaluated the detailed therapeutic effect of statin plus ezetimibe intensive therapy. Methods: For STEMI patients with non-IRA disease undergoing primary Percutaneous Coronary Intervention (PCI), 183 control STEMI patients without non-IRA disease undergoing primary PCI, and 200 STEMI patients with non-IRA disease undergoing primary PCI were introduced into this study. 200 STEMI patients with non-IRA disease undergoing primary PCI were divided into Normal group, Intensive group, Normal & Combined group, and Intensive & Combined group. The baseline information for each participant was recorded. Meanwhile, the physiological and biochemical indicators of each member with different treatments were collected after one-year follow-up. Results: For STEMI patients with non-IRA disease undergoing primary PCI, no differences could be detected in multiple indexes such as OCT examination results, age, stroke, etc. However, diabetes mellitus, smoking, and coronary Gensini score were different between different groups (P Conclusion: The results mentioned above suggested that pitavastatin combined with ezetimibe was an effective approach for STEMI patients with non-IRA disease undergoing primary PCI. The results obtained in this study have provided a novel method for the treatment of STEMI patients with non-IRA disease undergoing primary PCI. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|